Disease Site Focus:
Cutaneous/Melanoma, Leukemia/ Lymphoma
Research Focus Area:
Informatics, Diagnosis/ Prognosis
Type of Research:
Research Interest Statement:
My research interest is in improving the accuracy in the diagnosis and treatment of primary cutaneous T cell lymphoma CCTCL). My laboratory has focused on identifying novel genetic biomarkers that are specific to CTCL. We have identified a number of highly expressed genes in CTCL and demonstrated that DNA epigenetic modifications are abnormalties that contribute to alteration of gene expression. We are studying the role these genes in enhancing the early diagnosis of CTCL. . As there is not currently a cure for CTCL, we are directing research on treatment based on our focus on gene expression. We are testing the role of novel transcription regulatiors in enhancing toxicity of CTCL cells to identify potential therapeutic drugs for the treatment of CTCL.
“KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis” (NCT03816891)
“EL-1007-01-01: A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the Mycosis Fungoides (MF) or Sezary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)
Galderma – RD.06.SPR.118161
“A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderateto-Severe Atopic Dermatitis (249958)”
03/25/20 – 03/24/30
Kiniksa Pharmaceuticals, Ltd. – KPL-716-C201
“KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis (IRB 239539)”
11/22/19 – 04/16/30
Sasapu A, Dunn ALJ, Gardner J, Wong HK. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin. BMJ case reports. 2021 14(7). PMID: 34290015. PMCID: PMC8296810.
Mehdi SJ, Moerman-Herzog A, Wong HK. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma. BMC cancer. 2021 21(1):492. PMID: 33941102. PMCID: PMC8091512.
Kern M, Parks K, Wong HK. Nodule on the Neck. Cutis. 2021 107(5):241-254. PMID: 34288850.
Kayishunge D, Rick J, Ahmed A, [et al., including Wong H]. Progression of pyoderma gangrenosum with angioinvasive fungus. JAAD case reports. 2021 11:41-43. PMID: 33912634. PMCID: PMC8063694.
Nedosekin D, Wilson KD, Campbell K, [et al., including Wong HK]. Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab. JAAD case reports. 2021 9:57-60. PMID: 33665277. PMCID: PMC7898068.
Moerman-Herzog A, Mehdi SJ, Wong HK. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome. Cells. 2020 9(9). PMID: 32872487.
Matlock SM, Rush JL, Afzal W, [et al., including Wong HK]. Spontaneous ulcerations of the breast. Clinical and experimental dermatology. 2020 45(1):107-110. PMID: 30618053.
Guthrie J, King C, Battle L, [et al., including Wong H]. Pyoderma gangrenosum developing after chest tube placement in a patient with chronic lymphocytic leukemia. Cutis. 2019 104(5):E23-E26. PMID: 31886797.
Moerman-Herzog AM, Acheampong DA, Brooks AG, [et al., including Wong HK]. Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes. Oncotarget. 2019 10(49):5052-5069. PMID: 31489115. PMCID: PMC6707948.
Bayraktar M, Kockara S, Halic T, [et al., including Wong HK]. Local edge-enhanced active contour for accurate skin lesion border detection. BMC bioinformatics. 2019 20(Suppl 2):91. PMID: 30871471. PMCID: PMC6419326.
Wong HK. Developing BET-ter treatments for cutaneous T-cell lymphoma. Oncotarget. 2019 10(13):1267-1268. PMID: 30863486. PMCID: PMC6407685.
Pitch MA, Kim KH, Manning T, [et al., including Wong HK]. A diagnostically challenging case of CD8+ primary cutaneous gamma/delta T-cell lymphoma. Dermatology online journal. 2017 23(11). PMID: 29447636.
Kern M, Kim KH, Johnson G, [et al., including Wong HK]. Dermatitis herpetiformis presenting as pseudovasculitis. JAAD case reports. 2017 3(5):444-447. PMID: 28971130. PMCID: PMC5602830.
Mahmoud F, Shields B, Makhoul I, [et al., including Wong HK]. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer biology & therapy. 2017 18(7):451-469. PMID: 28513269. PMCID: PMC5639850.
Field H, Gao L, Motwani P, Wong HK. Erratum to: Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review. Dermatology and therapy. 2016 6(4):597. PMID: 27747468. PMCID: PMC5120638.
Field H, Gao L, Motwani P, Wong HK. Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review. Dermatology and therapy. 2016 6(4):579-595. PMID: 27590615. PMCID: PMC5120632.
Kaya S, Bayraktar M, Kockara S, [et al., including Wong HK]. Abrupt skin lesion border cutoff measurement for malignancy detection in dermoscopy images. BMC bioinformatics. 2016 17(Suppl 13):367. PMID: 27766942. PMCID: PMC5073935.
Kaffenberger BH, Zhang E, Duncan JR, [et al., including Wong HK]. Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease (GVHD) and GVHD-associated angiomatosis. The British journal of dermatology. 2016 175(4):782-4. PMID: 26875995.
Mishra A, La Perle K, Kwiatkowski S, [et al., including Wong H]. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer discovery. 2016 6(9):986-1005. PMID: 27422033. PMCID: PMC5388135.
Haverkos BM, Gru AA, Geyer SM, [et al., including Wong HK]. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2016 16 Suppl:S181-S190.e4. PMID: 27521316. PMCID: PMC4999299.
Wong HK. STAT Assays with a TWIST: Differentiating Sézary Syndrome from Erythrodermic Inflammatory Dermatitis. The Journal of investigative dermatology. 2016 136(7):1313-1315. PMID: 27342033.
Purnell JC, Williams BA, Shalin SC, Wong HK. Mucocutaneous findings associated with interleukin (IL)-17 inhibition. JAAD case reports. 2016 2(1):92-4. PMID: 27051840. PMCID: PMC4809481.
Scarisbrick JJ, Prince HM, Vermeer MH, [et al., including Wong H]. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 33(32):3766-73. PMID: 26438120. PMCID: PMC4979132.
Haverkos B, Tyler K, Gru AA, [et al., including Wong HK]. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. The oncologist. 2015 20(10):1161-6. PMID: 26306900. PMCID: PMC4591945.
Lee GL, Woods KL, Clark L, [et al., including Wong HK]. Short communication: mucocutaneous leishmaniasis in HIV-related immune reconstitution syndrome. AIDS research and human retroviruses. 2015 31(9):889-92. PMID: 26154873.
Kaffenberger B, Haverkos B, Tyler K, [et al., including Wong HK]. Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder. The American Journal of dermatopathology. 2015 37(8):604-13. PMID: 25839892. PMCID: PMC4510028.
Wong HK, Gibson H, Hake T, [et al.]. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. The Journal of investigative dermatology. 2015 135(8):2084-2092. PMID: 25806852.